SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) presents prompt glucose-lowering effects along with body weight loss in the over-weighted subjects with type 2 diabetes mellitus (T2DM) (5).